Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Judge throws book at Daniel Chapter One

This article was originally published in The Tan Sheet

Executive Summary

An administrative judge upholds the Federal Trade Commission's charges that supplement marketer Daniel Chapter One falsely advertised its shark cartilage and herbal formulations prevent, treat and cure cancer. The judge found the firm could not substantiate its claims with reliable scientific evidence and ordered the company to stop making false claims. FTC charged Daniel Chapter One with deceptive advertising in 2008 in an enforcement sweep that charged 11 firms with marketing false cancer remedies (1"The Tan Sheet" Sept. 22, 2008)

You may also be interested in...

FTC affirms cancer cures case ruling

Daniel Chapter One must notify customers it made deceptive and unsubstantiated cancer cure claims for its herbal products after failing in its appeal of an administrative law judge's ruling to uphold Federal Trade Commission charges. The commission's unanimous 1opinion, announced Dec. 24, says respondents Daniel Chapter One and James Feijo "lacked a reasonable basis to substantiate" claims their products BioShark, 7 Herb Formula and others inhibit tumor growth and are effective cancer treatments. Like other companies charged in FTC's 2008 enforcement sweep against bogus cancer cure claims, Providence, R.I.-based Daniel Chapter One is enjoined from making such claims without supporting scientific evidence (2"The Tan Sheet" Aug. 17, 2009, In Brief)

Cancer Claims Continue Attracting Federal Enforcement Actions

Herbal and supplement products allegedly making deceptive cancer cure claims prompted the Federal Trade Commission to file complaints against 11 firms, including five that rejected settlement offers and are contesting the complaints

Keeping Track: US FDA's Rejection Of First RMAT BLA Blemishes Otherwise Positive Week Of Non-Oncology News

The latest non-oncology drug development news and highlights from our US FDA Performance Tracker.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts